GoAI
Get started
Picard Medical, Inc. logo

Picard Medical, Inc.

PMI

AMEXHealthcareMedical - Devices

Open in GoAI

Previous close

$3.21

+$0.18 · +5.94%

Aug 21, 4:00 PM ET

PMI company overview

Regular session · ET · Market data may be delayed.

Company profile

Company website

Picard Medical, Inc., through its associated companies, is dedicated to the entire process of medical device commercialization, from initial design and manufacturing to production, distribution, marketing, and sales. A key product in its portfolio is the SynCardia TAH, a sophisticated total artificial heart specifically engineered to supplant a failing human heart in individuals afflicted with advanced cardiac disease. The firm's market presence extends across the United States, Europe, and other international regions. Established in 2021, Picard Medical maintains its primary operations in Tucson, Arizona, functioning as a direct subsidiary of Hunniwell Picard I, Llc.

Industry
Medical - Devices
Sector
Healthcare
Headquarters
US
CEO
Richard Fang
Listed since
Aug 29, 2025
Employees
75

Market position

Day range

Current $3.21

52-week range

Current $3.21

Open
$2.83
Previous close
$3.03
Volume
4.47M
6.58× average
Average volume
678.73K
Average daily volume
Market cap
6.61M USD
Beta
-2.64
Market reference 1
50-day average
$6.1598
-47.89% below average
200-day average
$54.2092
-94.08% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
128.52M USD
EV / EBITDA
-4.85×
Earnings yield
-20.93%
Free cash flow yield
-12.15%

Profitability & efficiency

Return on equity
-712.59%
Return on assets
-119.74%
Return on invested capital
-118.91%

Financial health

Current ratio
1.11×

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends59%-161%-381%-602%Gross margin, FY2022: -121.27%Gross margin, FY2023: -45.83%Gross margin, FY2024: -2.55%Gross margin, FY2025: 4.05%Operating margin, FY2022: -269.07%Operating margin, FY2023: -307.40%Operating margin, FY2024: -312.28%Operating margin, FY2025: -259.11%Net margin, FY2022: -271.53%Net margin, FY2023: -308.72%Net margin, FY2024: -479.50%Net margin, FY2025: -546.56%FY2022FY2023FY2024FY2025
Gross margin FY2022 -121.27%. Gross margin FY2023 -45.83%. Gross margin FY2024 -2.55%. Gross margin FY2025 4.05%. Operating margin FY2022 -269.07%. Operating margin FY2023 -307.40%. Operating margin FY2024 -312.28%. Operating margin FY2025 -259.11%. Net margin FY2022 -271.53%. Net margin FY2023 -308.72%. Net margin FY2024 -479.50%. Net margin FY2025 -546.56%.

Income trends

Revenue

4.94M USD+12.50%

Operating income

−12.8M USD+6.65%

Net income

−27M USD-28.24%
Income trends across reported periods8.25M USD−4.57M USD−17.39M USD−30.2M USDRevenue, FY2022: 4.11M USDRevenue, FY2023: 5.04M USDRevenue, FY2024: 4.39M USDRevenue, FY2025: 4.94M USDOperating income, FY2022: −11.07M USDOperating income, FY2023: −15.5M USDOperating income, FY2024: −13.71M USDOperating income, FY2025: −12.8M USDNet income, FY2022: −11.17M USDNet income, FY2023: −15.57M USDNet income, FY2024: −21.06M USDNet income, FY2025: −27M USDFY2022FY2023FY2024FY2025
Revenue FY2022 4.11M USD. Revenue FY2023 5.04M USD. Revenue FY2024 4.39M USD. Revenue FY2025 4.94M USD. Operating income FY2022 −11.07M USD. Operating income FY2023 −15.5M USD. Operating income FY2024 −13.71M USD. Operating income FY2025 −12.8M USD. Net income FY2022 −11.17M USD. Net income FY2023 −15.57M USD. Net income FY2024 −21.06M USD. Net income FY2025 −27M USD.
Metric (USD)FY2025FY2024FY2023FY2022
Revenue4.94M USD4.39M USD5.04M USD4.11M USD
Cost of goods sold4.74M USD4.5M USD7.35M USD9.1M USD
Gross profit200K USD−112K USD−2.31M USD−4.99M USD
Research and development3M USD3.38M USD2.21M USD1.9M USD
Selling, general, and administrative10M USD10.22M USD10.98M USD4.18M USD
Operating expenses13M USD13.6M USD13.19M USD6.08M USD
Interest income——2K USD9K USD
Interest expense—3.07M USD140K USD5K USD
Depreciation and amortization512K USD543K USD585K USD545K USD
Operating income−12.8M USD−13.71M USD−15.5M USD−11.07M USD
Net income−27M USD−21.06M USD−15.57M USD−11.17M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
0%
0 beats, 1 miss, 1 met estimate
Average EPS surprise
-51.67%
2 comparable reports
Latest EPS result
-3.05
Estimate -1.5 · Miss by 103.33%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates-0.08-1.85-3.62-5.39Q3 '25No estimateQ4 '25No estimateQ1 '26No estimateQ2 '26MetQ3 '26MissQ4 '26Estimate
Q3 2025, reported Sep 11, 2025: actual -0.1, estimate —, surprise —, Comparison unavailable. Q4 2025, reported Nov 14, 2025: actual -0.19, estimate —, surprise —, Comparison unavailable. Q1 2026, reported Mar 25, 2026: actual -3, estimate —, surprise —, Comparison unavailable. Q2 2026, reported May 15, 2026: actual -5, estimate -5, surprise 0.00%, Met estimate. Q3 2026, reported Aug 19, 2026: actual -3.05, estimate -1.5, surprise -103.33%, Miss. Q4 2026, reported Nov 13, 2026: actual —, estimate -1.5, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates3.11M2.36M1.61M857.65KQ3 '25No estimateQ4 '25No estimateQ1 '26No estimateQ2 '26MetQ3 '26BeatQ4 '26Estimate
Q3 2025, reported Sep 11, 2025: actual 2.13M USD, estimate —, surprise —, Comparison unavailable. Q4 2025, reported Nov 14, 2025: actual 1.19M USD, estimate —, surprise —, Comparison unavailable. Q1 2026, reported Mar 25, 2026: actual 1.01M USD, estimate —, surprise —, Comparison unavailable. Q2 2026, reported May 15, 2026: actual 1.15M USD, estimate 1.15M USD, surprise 0.00%, Met estimate. Q3 2026, reported Aug 19, 2026: actual 2.95M USD, estimate 1.55M USD, surprise +90.58%, Beat. Q4 2026, reported Nov 13, 2026: actual —, estimate 1.55M USD, surprise —, Comparison unavailable.

PMI news

globenewswire.com

Picard Medical Reports Second Quarter 2026 Financial Results

- Revenue Increases 39% and Net Loss Decreases 16%- Year-to-Date Revenue Increases 50%, with ~$0.9 Million in Gross Profit TUCSON, Ariz., Aug. 19, 2026 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE American: PMI)…

Read source
gurufocus.com

/C O R R E C T I O N -- Fundstrat Capital/

/C O R R E C T I O N -- Fundstrat Capital/ PR Newswire NEW YORK, June 9, 2026 In the

Read source
gurufocus.com

/C O R R E C T I O N -- Fundstrat Capital/

/C O R R E C T I O N -- Fundstrat Capital/ PR Newswire NEW YORK, June 3, 2026 In the

Read source
globenewswire.com

Picard Medical / SynCardia Presents Emperor Total Artificial Heart Architecture for the First Time at IEEE EMBC 2026

–First public scientific presentation provides the biomedical engineering community with its first detailed view of the next-generation total artificial heart platform– –First public scientific presentation provides the…

Read source
globenewswire.com

Picard Medical / SynCardia to Present Next-Generation Emperor Total Artificial Heart Technology at IEEE EMBC 2026

-First scientific presentation of the Emperor Drive System architecture to the biomedical engineering community- TUCSON, Ariz., July 27, 2026 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE American: PMI) ("Picard" or the…

Read source
globenewswire.com

Picard Medical Receives NYSE American Acceptance of Compliance Plan

-Company continues advancing long-term growth strategy under accepted compliance plan- -Company continues advancing long-term growth strategy under accepted compliance plan-

Read source

Corporate actions

Corporate action history

Stock split

Effective Aug 3, 2026

1:50

PMI peers

National HealthCare Corporation logo

NHC

National HealthCare Corporation

$233.4

-1.41%

Perspective Therapeutics, Inc. logo

CATX

Perspective Therapeutics, Inc.

$3.30

+2.80%

Electromed, Inc. logo

ELMD

Electromed, Inc.

$39.45

-1.38%

Lineage Cell Therapeutics, Inc. logo

LCTX

Lineage Cell Therapeutics, Inc.

$1.08

0.00%

InfuSystem Holdings, Inc. logo

INFU

InfuSystem Holdings, Inc.

$12.21

+0.08%

Protalix BioTherapeutics, Inc. logo

PLX

Protalix BioTherapeutics, Inc.

$2.38

0.00%

ETFs holding PMI

Funds reporting this stock among their holdings, ordered by reported position size.

Vanguard Morningstar Total Stock Market ETF logoVanguard Morningstar Total Stock Market ETFVTI
Market value
221.34K
Weight
0.00%
AUM
2.3T USD
Expense ratio
0.03%
Price / 1D
$378.24+0.44%

Continue in GoAI

Research PMI

research.disclaimer